perceptive™ discovery

From Concept to Clinic: Best Practices for Radioligand Therapy Development

Navigating Early Development, Safety, Dosimetry, and Clinical Translation

The Complexity of Radio Ligand Therapy Development

Radioligand therapies (RLTs) combine the precision of targeted ligands with the power of radioactive payloads. Because these compounds span multiple disciplines—imaging, radiochemistry, pharmacology, and regulatory science—RLT development demands careful planning from preclinical research through to first-in-human studies. This guide outlines best practices for researchers and developers to mitigate risk, reduce development timelines, and improve the odds of clinical success.

perceptive discovery

Laying the Groundwork: Preclinical Strategy and Pharmacology

A robust early-phase strategy provides the scientific foundation for successful clinical translation. Key priorities include demonstrating target engagement, understanding pharmacodynamics, and selecting the right animal models.

Best Practices:

- Design proof-of-concept studies to assess tumor targeting and therapeutic activity.
- Use in vitro/ex vivo binding assays to evaluate target specificity and internalization.
- Combine in vivo imaging with ex vivo gamma counting and autoradiography to track drug distribution.
- Choose xenograft, syngeneic, or orthotopic models appropriate to tumor biology and immune context.



perceptive discovery

Optimizing the Construct: Radiochemistry & Immunoreactivity

Chemical integrity, stability, and biologic targeting must be preserved when labeling ligands with radioisotopes. Method development in radiochemistry is essential for reliable clinical translation.

Best Practices:

- Perform radiolabeling method development to support alpha, beta, and gamma-emitting isotopes conjugated to small molecules and biologics.
- Conduct high-performance liquid chromatography method development, measure specific activity, optimize formulation, and execute serum stability studies.
- Complete Immunoreactivity assays for the successful translation of biologic radiopharmaceuticals.
- Explore good manufacturing practice development, validation and production capabilities along with shipping of tracers and/or setup of chemistry networks to support multi-site clinical studies.

perceptive discovery

Early Risk Identification: Safety Pharmacology and Toxicology

Characterizing potential toxicities early prevents delays later. Imaging plays a key role in visualizing off-target accumulation and understanding biological effects of both the ligand and radionuclide.

Best Practices:

- Include clinical markers (CBC, chemistry panels, urinalysis) alongside imaging-based biodistribution.
- Monitor radiation exposure in relevant organs using quantitative imaging or dosimetry modeling.
- Tailor safety endpoints to the compound's mechanism of action and route of administration

perceptive discovery

Predictive Modeling: Animal Dosimetry and Human Extrapolation

Understanding the radiation profile across tissues is crucial for dose planning. Small animal imaging can provide quantitative input for human dosimetry estimates.

Best Practices:

- Run animal biodistribution and dosimetry studies to predict the radiation and dosimetry profile of the radiopharmaceutical in humans.
- Perform imaging and gamma counting dosimetry studies in small animals and diverse higher animal models.
- Conduct specialized dosimetry analysis, including voxel-based assessment, advanced spine dosimetry following intrathecal administration and extrapolation from one radioisotope to another.

perceptive discovery

Designing for Success: Translation and First-in-Human Studies

Moving into first-in-human studies requires strategic planning that integrates prior imaging, dosimetry, and pharmacology work.



Best Practices:

- Develop a tailored clinical trial design that accounts for radiation safety, dosimetry, and patient selection criteria specific to radioligand therapies.
- Establish imaging and biomarker strategies to assess target engagement, pharmacokinetics, and early efficacy in human subjects.
- Ensure GMP-grade production and robust quality control processes are in place to support consistent radiotracer supply for clinical trials.

perceptive discovery

Application in Practice: Targeted Alpha Therapy in TNBC

As an illustrative example, a radiolabeled antibody (e.g., DOTA-hTAB04) showed strong tumor uptake in preclinical imaging and a dramatic 89% tumor volume reduction following a single alpha-emitter dose, with statistically significant survival benefits.

Insights:

- Longitudinal imaging supported dose selection.
- Combined pharmacology and imaging enabled rapid proof-of-concept.
- Biodistribution and dosimetry studies supported safe translation.



Anti tumour-muc-1 antibody labelled with DOTA and imaged in mice using ^{111}In.

Kelly V.J.et al Theranostics 2020, Vol. 10, Issue 15



Mice treated with ^{225}Ac-labelled anti tumour-muc-1 antibody

A) Tumor volume in animals administered with ^{225}Ac-DOTA-hTAB004 (red) compared to control animals adminitered DOTA-hTAB004 (blue) as monitored for the duration of the study. Intra-group comparisons of percentage change in tumor volume at each study day; *P<0.05, # P<0.01, ^ P<0.001. **(B)** Kaplan-Meier survival curves showing 100% survival in treatment group until the end of the study (D=48; red) and 0% survival in control group (blue).

Kelly V.J.et al Theranostics 2020, Vol. 10, Issue 15

perceptive discovery

perceptive™ discovery

Bringing it All Together

Radioligand therapy development is a complex but high-impact endeavor. When executed with scientific rigor and cross-disciplinary coordination, early-phase studies can de-risk clinical entry and accelerate success.

Checklist for Success:

- [ ] Align pharmacology, chemistry, and imaging early
- [ ] Plan safety and dosimetry studies with human application in mind
- [ ] Prepare for translation with GMP and regulatory foresight